OakChart

Lantern Pharma Inc

LTRNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.4810+0.0180 (3.89%)
2026-11-12 04:35 CET
Market cap
7.18 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-18.65 USD m
Free cash flow, TTM
-14.08 USD m
EPS diluted, TTM
-1.61
P/E
-
Compare

Price

LTRN against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.004.00942K1.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LTRNclose 0.4820-day 0.6250-day 1.04200-day 2.350.4852w high

88.9% under the 52-week high of 4.34 on 1 Jul 2026. 52-week low 0.45 on 10 Nov 2026. Last 15 sessions, 86.7% high to low

Volume 0.65× normal · the line is the 50-bar volume average

Profile

LTRN
52-week range, 1% of the way up
0.454.34

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Employees16
IPOJun 11, 2020
Beta2.50
ATR, 14d0.11
Rel volume0.65
Short float7.96%
Insider own22.23%
Inst own26.51%

Snapshot

6 groups

Valuation

Index-
Market Cap7.19M
Enterprise Value-0.13M
Income-18.65M
Sales0.00M
Book/sh-0.25
Cash/sh0.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOJun 11, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.98
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.96
Current Ratio1.96
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.61
EPS next Y-2.02
EPS next Q-0.35
EPS this Y-3.82%
EPS next Y-23.93%
EPS next 5Y-10.36%
EPS past 3/5Y-6.13% -10.59%
Sales past 3/5Y- -
EPS Y/Y TTM9.68%
Sales Y/Y TTM-
EPS Q/Q-41.76%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-50.00% -

Ownership

Insider Own22.23%
Insider Trans3.01%
Inst Own26.51%
Inst Trans-1.14%
ROA-143.36%
ROE-400.92%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-23.01%
SMA50-53.90%
SMA200-79.51%
Trades-

Technical

Shs Outstand12.76M
Shs Float11.61M
Short Float7.96%
Short Ratio3.80
Short Interest0.92M
52W High4.34 -88.92%
52W Low0.45 6.89%
Volatility19.76% 15.37%
ATR (14)0.11
RSI (14)28.89
Beta2.50
Rel Volume0.65
Avg Volume243.07K
Volume157,211

Performance

Perf Week-18.00%
Perf Month-32.32%
Perf Quarter-81.71%
Perf Half Y-80.84%
Perf YTD-84.13%
Perf Year-86.41%
Perf 3Y-85.42%
Perf 5Y-95.04%
Perf 10Y-
Recom1.00
Target Price22.00
Prev Close0.46
Price0.48
Change %3.89%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 07, 2021InitiatedHH.C. WainwrightBuy$32+6,552.8%

Peers

Mkt cap
TickerCompanyMkt cap
RXRXRecursion Pharmaceuticals Inc2.24B
HYFTMindWalk Holdings Corp49.00M
ABSIAbsci Corp1.74B
TPSTTempest Therapeutics Inc7.94M
ACTUActuate Therapeutics Inc16.63M
CRDFCardiff Oncology Inc59.54M
KZIAKazia Therapeutics Limited ADR84.92M
OSTXOS Therapies Inc45.64M
SDGRSchrodinger Inc2.37B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Schalop Lee TroyDirectorMay 12 '26Buy2.0648,544100,00148,544May 14 04:10 PM
KEYSER D JEFFREYDirectorMay 12 '26Buy2.0648,544100,00194,303May 14 04:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
MEDXHorizon Kinetics Medical ETFAUM: 17.88M
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.570-0.380-0.5700.000.001
2026Q12026-05-15-0.300-0.360-0.2960.000.001
2025Q42026-03-30-0.360-0.460-0.3620.000.001
2025Q32025-11-13-0.390-0.470-0.3860.000.001
2025Q22025-08-13-0.400-0.440-0.4020.000.001
2025Q12025-05-15-0.420-0.490-0.4210.000.001
2024Q42025-03-27-0.540-0.510-0.5450.000.001
2024Q32024-11-07-0.420-0.560-0.4190.000.001
2024Q22024-08-08-0.460-0.550-0.4610.000.001
2024Q12024-05-09-0.510-0.430-0.5070.000.001
2023Q42024-03-18-0.390-0.400-0.3880.000.002
2023Q32023-11-08-0.290-0.483-0.2910.000.003
2023Q22023-08-09-0.440-0.433-0.4370.000.003
2023Q12023-05-09-0.360-0.480-0.3560.000.001
2022Q42023-03-20-0.310-0.470-0.3110.000.002
2022Q32022-11-07-0.210-0.480-0.2090.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.370-1.320-0.9500.000.00
2021FY-1.130-1.217-1.1340.000.00
2022FY-1.310-1.480-1.3140.000.00
2023FY-1.470-1.507-1.4720.000.00
2024FY-1.930-1.915-1.9310.000.00
2025FY-1.570-1.670-1.5700.000.00
2026FY--1.630--0.00
2027FY--2.020--0.00
2028FY--2.110---
2029FY--2.200---
2030FY--2.380---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-181000.000.000.00
2026Q3S2026-04-201000.000.000.00
2026Q3R2026-10-28100-0.35-0.35-0.35
2026Q3R2026-08-14110-0.35-0.35-0.35
2026Q3R2026-05-18100-0.38-0.38-0.38
2026Q3R2026-03-31100-0.38-0.38-0.38
2026Q3E2026-10-28100-0.35-0.35-0.35
2026Q3E2026-08-14110-0.35-0.35-0.35
2026Q3E2026-05-18100-0.38-0.38-0.38
2026Q3E2026-03-31100-0.38-0.38-0.38
2026Q2S2026-05-181000.000.000.00
2026Q2S2026-05-161000.000.000.00
2026Q2S2026-05-151000.000.000.00

Estimate history

EPS, annual-0.276-0.388-0.95-1.134-1.314-1.472-1.931-1.571-1.6127
Period20182019202020212022202320242025TTM
EPS, quarterly-0.461-0.419-0.545-0.421-0.402-0.386-0.362-0.296-0.569
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual6.2656.2656.22111.08910.85710.72110.78511.25512.759
Period20182019202020212022202320242025MRQ
Shares, quarterly10.75910.78510.78510.78510.78511.0411.25511.25512.759
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.190.170.150.100.000.00-0.00
Gross Profit-0.02-0.02-0.19-0.17-0.15-0.10-0.00-0.000.00
Selling, General and Administrative Excl. Other15.4517.9622.0317.7014.2812.495.902.431.73
Research and Development8.7011.5116.1311.898.607.572.240.950.57
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-15.47-17.98-22.22-17.88-14.43-12.59-5.91-2.43-1.73
Interest Expense0.000.000.000.000.00--0.000.00
Unusual Expense2.130.000.000.000.490.000.00--
Net Income Before Taxes-18.65-17.12-20.78-15.96-14.26-12.36-5.91-2.43-1.73
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-18.65-17.12-20.78-15.96-14.26-12.36-5.91-2.43-1.73
Net Income From Continuing Operations-18.65-17.12-20.78-15.96-14.26-12.36-5.91-2.43-1.73
Net Income-18.65-17.12-20.78-15.96-14.26-12.36-5.91-2.43-1.73
EPS (Recurring)-1.38-1.57-1.93-1.47-1.28-1.13-0.95-0.39-0.28
EPS (Basic, Before Extraordinaries)-1.61-1.57-1.93-1.47-1.31-1.13-0.95-0.39-0.28
EPS (Diluted)-1.61-1.57-1.93-1.47-1.31-1.13-0.95-0.39-0.28
EBITDA-15.45-17.96-22.03-17.70-14.28-12.49-5.90-2.43-1.73
Non-Operating Income (Expense)-1.060.861.441.920.670.230.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.890.650.651.021.190.961.190.120.19
Shares Outstanding12.7611.2510.7810.7210.8611.096.226.276.27
Market Capitalization7.187.1834.4046.5265.5889.38119.69120.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.050.05
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.00-0.05-0.05
Selling, General and Administrative Excl. Other3.503.404.204.354.654.775.855.13
Research and Development1.791.722.742.443.073.264.273.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.51-3.41-4.20-4.35-4.65-4.77-5.90-5.18
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense2.130.000.000.000.000.000.000.00
Net Income Before Taxes-7.07-3.33-4.07-4.18-4.33-4.54-5.88-4.51
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.07-3.33-4.07-4.18-4.33-4.54-5.88-4.51
Net Income From Continuing Operations-7.07-3.33-4.07-4.18-4.33-4.54-5.88-4.51
Net Income-7.07-3.33-4.07-4.18-4.33-4.54-5.88-4.51
EPS (Recurring)-0.45-0.30-0.36-0.39-0.40-0.42-0.54-0.42
EPS (Basic, Before Extraordinaries)-0.57-0.30-0.36-0.39-0.40-0.42-0.54-0.42
EPS (Diluted)-0.57-0.30-0.36-0.39-0.40-0.42-0.54-0.42
EBITDA-3.50-3.40-4.20-4.35-4.65-4.77-5.85-5.13
Non-Operating Income (Expense)-1.440.080.130.170.320.240.020.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.290.260.200.140.160.150.200.18
Shares Outstanding12.7611.2511.2511.0410.7810.7810.7810.78
Market Capitalization7.1815.3233.8946.9834.0838.1834.4039.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments10.1224.0141.3055.7470.7319.231.230.45
Short Term Receivables0.030.100.860.590.180.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.651.141.182.391.811.010.000.00
Total Current Assets10.8025.2543.3458.7272.7220.241.230.45
Net Property, Plant & Equipment0.110.290.280.100.220.020.010.00
Total Investments and Advances0.000.000.000.001.000.000.000.00
Intangible Assets-----0.000.000.00
Deferred Tax Assets0.00-------
Other Assets0.130.040.030.020.020.100.190.00
Total Assets11.0425.5743.6558.8473.9520.361.430.45
Short Term Debt Incl. Current Port. of LT Debt0.080.190.170.050.150.000.000.00
Accounts Payable4.424.142.512.752.170.550.490.12
Other Current Liabilities0.00-0.000.00-0.00-0.000.000.000.54
Total Current Liabilities4.504.332.682.802.330.550.490.65
Long Term Debt0.000.050.060.000.050.110.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.00-------
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities4.514.382.742.802.380.660.490.65
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.010.01
Common Equity6.5321.1940.9156.0471.5719.700.93-0.21
Total Shareholders Equity6.5321.1940.9156.0471.5719.700.94-0.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity6.5321.1940.9156.0471.5719.700.94-0.20
Total Liabilities & Stockholders Equity11.0425.5743.6558.8473.9520.361.430.45
Book Value Per Share0.581.963.825.166.453.170.15-0.03
Tangible Book Value Per Share0.581.963.825.166.453.170.15-0.03
Full-Time Employees162421231615--
Price to Book Ratio-1.911.291.021.111.246.085.57-
Return on Assets-93.52-60.04-31.15-21.48-26.22-54.22-257.99-
Return on Equity-123.51-66.93-32.93-22.35-27.09-57.24-654.95-
Return on Invested Capital-262.00-97.84-38.96-25.45-17.26-29.83-257.42-
Quick Ratio2.405.8316.1820.9931.2636.642.520.68
Current Ratio2.405.8316.1820.9931.2636.642.520.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-18.65-17.12-20.78-15.96-14.26-12.36-5.91-2.43-1.73
Depreciation0.020.020.190.170.150.100.000.00-0.00
Other Funds (Non Cash)5.060.790.550.901.951.071.190.120.19
Funds from Operations-13.58-16.31-20.04-14.88-12.16-11.19-4.71-2.31-1.54
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.500.642.230.54-0.610.60-0.940.180.27
Cash from Operating Activities-14.08-15.68-17.81-14.35-12.77-10.59-5.65-2.13-1.27
Capital Expenditures-0.00-0.00-0.01-0.02-0.03-0.02-0.02-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.01
Purchase or Sale of Investments9.1711.063.38-0.910.21-19.520.000.000.00
Purchase of Investments-6.28-14.72-17.28-8.20-3.91-19.580.000.000.00
Sale Or Maturity of Investments15.4525.7820.667.284.120.060.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities9.1711.063.37-0.930.18-19.53-0.02-0.010.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.491.500.07-0.50-2.1863.4223.562.920.00
Repurchase of Common Pref Stock0.000.000.00-0.50-2.48-0.940.000.000.00
Sale of Common Pref Stock5.491.500.070.000.3064.3623.562.920.00
Proceedsfrom Stock Options5.481.480.000.000.0064.2223.502.920.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.110.000.00
Change in Long Term Debt0.000.000.000.000.000.000.110.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.110.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.000.000.54
Other Financing Activities Uses0.000.000.000.000.000.00-0.000.000.00
Cash from Financing Activities5.491.500.07-0.50-2.1863.4223.662.920.54
Exchange Rate Effect0.020.03-0.05-0.03-0.010.00---
Net Change in Cash0.60-3.09-14.43-15.81-14.7833.3018.000.79-0.73
Free Cash Flow-14.08-15.68-17.83-14.37-12.80-10.61-5.67-2.13-
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.366.3210.1212.3615.9019.72
Short Term Receivables0.000.000.030.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.100.730.651.101.301.10
Total Current Assets8.467.0610.8013.4617.2020.82
Net Property, Plant & Equipment0.060.080.110.130.180.24
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets--0.00---
Other Assets0.080.080.130.040.040.04
Total Assets8.607.2211.0413.6317.4221.10
Short Term Debt Incl. Current Port. of LT Debt0.040.060.080.090.130.16
Accounts Payable4.283.724.423.954.754.12
Other Current Liabilities-0.00-0.000.00-0.00-0.00-0.00
Total Current Liabilities4.323.784.504.044.884.29
Long Term Debt0.000.000.000.000.010.03
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.00---
Other Liabilities7.500.000.000.000.000.00
Total Liabilities11.823.784.514.044.904.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-3.223.456.539.5912.5216.78
Total Shareholders Equity-3.223.456.539.5912.5216.78
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-3.223.456.539.5912.5216.78
Total Liabilities & Stockholders Equity8.607.2211.0413.6317.4221.10
Book Value Per Share-0.250.310.580.871.161.56
Tangible Book Value Per Share-0.250.310.580.871.161.56
Full-Time Employees--16---
Price to Book Ratio-1.912.363.493.752.031.80
Return on Assets-143.36-112.37-93.52-86.16-72.63-65.35
Return on Equity-400.92-157.37-123.51-104.58-88.59-75.66
Return on Invested Capital--96.62-62.35-43.57-34.55-26.99
Quick Ratio1.961.872.403.333.524.86
Current Ratio1.961.872.403.333.524.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.07-3.33-4.07-4.18-4.33-4.54
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)4.050.320.440.260.010.09
Funds from Operations-3.02-3.01-3.63-3.92-4.32-4.44
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.08-0.760.84-0.660.380.07
Cash from Operating Activities-2.94-3.77-2.79-4.57-3.94-4.38
Capital Expenditures0.000.00-1E-06-0.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.694.25-1.705.933.593.24
Purchase of Investments0.000.00-4.20-2.08-3.46-4.98
Sale Or Maturity of Investments0.694.252.508.017.058.22
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.694.25-1.705.933.593.24
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.990.000.530.970.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.990.000.530.970.000.00
Proceedsfrom Stock Options3.990.000.530.960.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.990.000.530.970.000.00
Exchange Rate Effect-0.000.020.00-0.000.030.00
Net Change in Cash1.740.49-3.972.33-0.32-1.13
Free Cash Flow-2.94-3.77-2.79-4.57-3.94-4.38

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.96%0.9M11.6M230.86K
2026-10-153.35%0.4M11.6M185.62K
2026-09-304.18%0.5M11.6M172.60K
2026-09-155.61%0.6M9.9M139.23K
2026-08-315.68%0.6M9.9M150.72K
2026-08-146.97%0.7M9.9M175.55K
2026-07-318.83%0.8M9.6M216.03K
2026-07-159.45%0.9M10.0M251.88K
2026-06-309.64%0.9M9.6M534.06K
2026-06-1514.19%1.4M9.6M678.92K
2026-05-2917.34%1.5M8.5M654.67K
2026-05-1522.33%1.9M8.5M627.70K
2026-04-3024.14%2.0M8.4M581.39K
2026-04-1521.03%1.7M8.3M551.66K
2026-03-3124.95%2.2M8.8M477.31K
2026-03-133.60%0.3M8.7M54.50K
2026-02-273.77%0.3M8.7M59.87K
2026-02-133.54%0.3M8.7M60.50K
2026-01-303.55%0.3M8.7M63.86K
2026-01-153.62%0.3M8.7M80.30K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.002.800.100.00039.000.000.0000.0000.000
call2.000.002.800.000.0000.000.000.0000.0000.000
call3.000.002.800.000.0000.000.000.0000.0000.000
call4.000.002.800.000.0000.000.000.0000.0000.000
call5.000.002.800.000.0000.000.000.0000.0000.000
put1.000.002.350.000.0000.000.000.0000.0000.000
put2.000.003.400.000.0000.000.000.0000.0000.000
put3.000.654.400.000.0000.000.000.0000.0000.000
put4.001.655.400.000.0000.000.000.0000.0000.000
put5.002.656.400.000.0000.000.000.0000.0000.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-21ARSAnnual report to security holders. 2025-12-31SEC
2026-10-19DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-19SEC
2026-10-13SCHEDULE 13G/ASEC
2026-10-08PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-08SEC
2026-10-018-KCurrent report2026-09-25SEC
2026-09-308-KCurrent report2026-09-28SEC
2026-09-30424B5SEC
2026-09-248-KCurrent report2026-09-23SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-04SCHEDULE 13GSEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-23SCHEDULE 13G/ASEC
2026-06-18EFFECTEffectiveness filing by commission orderSEC
2026-06-12S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-06-028-KCurrent report2026-06-01SEC
2026-05-21DNotice of sales of securities on Form D (Regulation D)SEC
2026-05-15SCHEDULE 13D/ASEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-14424B5SEC
2026-04-3010-K/A2025-12-31SEC
2026-04-16SCHEDULE 13D/ASEC
2026-04-108-KCurrent report2026-04-09SEC
2026-04-03SCHEDULE 13GSEC
2026-03-30424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05200.00K200
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Empery Asset Management, LP6.60%
CM Management, LLC3.92%
VANGUARD CAPITAL MANAGEMENT LLC3.33%
RENAISSANCE TECHNOLOGIES LLC2.28%
BIOS Capital Management, LP1.95%
UBS Group AG0.98%
GEODE CAPITAL MANAGEMENT, LLC0.80%
VANGUARD FIDUCIARY TRUST CO0.39%
CITADEL ADVISORS LLC0.38%
Westside Investment Management, Inc.0.37%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.65%
VANGUARD EXTENDED MARKET INDEX FUND0.64%
Fidelity Extended Market Index Fund0.39%
Horizon Kinetics Medical ETF0.20%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.12%
U.S. Social Core Equity 2 Portfolio0.09%
U.S. SMALL CAP PORTFOLIO0.08%
Fidelity Nasdaq Composite Index Fund0.06%
VANGUARD BALANCED INDEX FUND0.04%

OakChart. LTRN. Cached 15 minutes.